Form 4: Nautilus Biotechnology CEO Sujal Patel Increases Stake in Company

Nautilus Biotechnology's CEO, Sujal M. Patel, recently acquired additional shares of common stock, increasing his beneficial ownership.

Summary

• On March 8, 2024, Sujal M. Patel, CEO, President, and Secretary of Nautilus Biotechnology, purchased 2,430 shares of common stock at a weighted average price of $2.9885.
• The shares were bought in the price range of $2.96 to $3.00.
• Following this transaction, Patel directly owns 10,052,444 shares.
• On March 11, 2024, Patel purchased 12,044 shares of common stock at a weighted average price of $2.8409.
• The shares were bought in the price range of $2.75 to $3.00.
• Following this transaction, Patel directly owns 10,064,488 shares.
• Patel also indirectly owns 1,814,035 shares through the Sujal Patel 2020 Children's Trust and 5,280,476 shares through PFV I, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's increased stake suggests confidence, but it's a routine Form 4 filing.

Positives

• The CEO's purchase of additional shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's performance and future prospects. It can be a positive signal, but should be considered alongside other factors.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive sign.

Key Dates